Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-486 + Lenalidomide + Obinutuzumab in R/R Indolent B-Cell Lymphoma
NCT04578600Phase 1Completed
- Start
- Oct 2020
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of azacitidine in indolent B-cell lymphoma. Primary endpoint: Incidence of adverse events. Started Oct 2020; status: completed.
02
Drugs
azacitidine
03
Conditions
indolent B-cell lymphoma
Beyond the preview
Go deeper on NCT04578600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04578600.